KDM4A-AS1, ZFPM2-AS1, AC099850.3, MKLN1-AS, and BACE1-AS may provide biomarkers for drug therapy at different tumor stages and gene mutation loads, thus facilitating precise treatment for patients with LIHC. Here, MKLN1 is linked to neoplasm.